Therapeutic efficacy of idebenone on cognitive impairment in patients with Parkinson's disease
Objective To investigate the therapeutic effects of idebenone in patients with Parkinson's disease-related cognitive impairment and to explore its mechanisms of action.Methods A total of 216 patients with Parkinson's disease-related cognitive impairment who were hospitalized in the The First Affiliated Hospital of Shandong First Medi-cal University from January 2017 to January 2024 were included.The patients were randomly divided into the conven-tional treatment group(n=82)and the idebenone treatment group(n=134).The changes of the Montreal Cognitive Assessment(MoCA)and its subdomain cognitive scores,the Mini-Mental State Examination(MMSE),the Unified Parkinson's Disease Rating Scale Ⅲ(UPDRS-Ⅲ),the Cholinergic Pathways Hyperintensities Score(CHIPS),inter-leukin-6(IL-6),peripheral blood superoxide dismutase(SOD),liver function,and kidney function were monitored for both groups before drug treatment and after 12 months of continuous drug treatment.Results There were no statisti-cally significant differences in general data,Hoehn-Yahr(H-Y)staging,various scale scores and hematological indica-tors before treatment(P>0.05).After 12 months of drug treatment,the increase in MoCA scores and their single-do-main visuospatial executive ability and language was higher in the idebenone treatment group than in the conventional treatment group(P<0.05),and the decrease in UPDRS-Ⅲscores was even more pronounced(P<0.05).The IL-6 lev-els in the idebenone treatment group decreased,while those in the conventional treatment group increased,with a statis-tically significant difference between the two groups(P<0.05).The SOD levels in the idebenone treatment group in-creased,while those in the conventional treatment group decreased,with a statistically significant difference between the two groups(P<0.05).There were no statistically significant differences in liver and kidney function-related indicators between the two groups(P>0.05).After adjusting for pre-treatment CHIPS scores,disease duration,and age covari-ates,the CHIPS score in the idebenone treatment group was 2.19 points lower than that in the conventional treatment group(F=229.16,P<0.01,R2=0.91,adjusted R2=0.90).Conclusion Idebenone can significantly alleviate cognitive impairment,improve motor symptoms,delay the damage of white matter hyperintensities to the cholinergic pathways,increase peripheral blood SOD levels,and reduce IL-6 levels in patients with Parkinson's disease.
万方数据
维普
